TNF Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNFA research report →
Price Chart
About the company
TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm dedicated to developing advanced therapeutic platforms that tackle the root causes of diseases, rather than just managing symptoms. Its flagship drug platform, MYMD-1, is a small molecule currently undergoing clinical trials.
- CEO
- Mitchell Glass
- IPO
- 2014
- Employees
- 2
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on TNFA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.18M
- P/E
- -0.63
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.17
- EV/EBITDA
- -0.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -77.19%
- ROIC
- -72.76%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-9,847,357
- Net Income
- $-11,627,122+50.2%
- EPS
- $-8.66+99.2%
- OCF Growth
- -1.0%
- FCF Growth
- -1.0%
- 52W High
- $195.00
- 52W Low
- $3.24
- 50D MA
- $7.03
- 200D MA
- $33.82
- Beta
- 2.28
- RSI (14)
- 48
- Avg Volume
- 1.68M
No earnings-call transcripts are available for TNFA yet.
- Free Float
- 100.0%
- Shares Outstanding
- 1.77M
- Float Shares
- 1.77M
of shares held by institutions
29 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sandy Spring Bank | 116 | 0 |
| Legacy Investment Solutions, LLC | 60 | ▲ 60 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 25 | RAUCH GARY M | other | 75,000 |
| Apr 17, 25 | RHODES IAN | other | 25,000 |
| Apr 17, 25 | Glass Mitchell | other | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TNFA coverage
Recent articles, reports, and earnings notes.
No research on TNFA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TNFA report →TNF Pharmaceuticals (NASDAQ:TNFA) Trading 0.8% Higher – What’s Next?
defenseworld.net · Apr 24
Altimmune (NASDAQ:ALT) versus TNF Pharmaceuticals (NASDAQ:TNFA) Head-To-Head Comparison
defenseworld.net · Apr 5
Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS”
businesswire.com · Sep 25
TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing
businesswire.com · Sep 24
TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
businesswire.com · Sep 17
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
businesswire.com · Sep 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.